George Talbot, MD

Talbot Advisors LLC
PO Box 7440
Saint Davids PAUSA
19087-7440

Biographical Sketch:
Dr. Talbot received his Bachelor of Arts degree in Religion and Psychology from Wesleyan University and his Doctorate in Medicine from the Yale University School of Medicine. He completed his training in Internal Medicine and Infectious Diseases at the University of Pennsylvania hospitals, and then assumed successive faculty positions at the University of Pennsylvania School of Medicine, becoming Associate Professor of Medicine (Infectious Diseases Section) and Adjunct Faculty Member, Clinical Epidemiology Unit (Section of General Internal Medicine), Dr. Talbot’s main research interests were the epidemiology and management of nosocomial infections, including those occurring in patients with acute leukemia (especially invasive aspergillosis), as well as clinical trials of new antimicrobial agents. Dr Talbot currently provides consultative services in anti-infective drug development through his company, Talbot Advisors LLC, which he founded in 2000. He sits on the scientific advisory boards of Calixa Therapeutics, Inc. and Actelion Pharmaceuticals, as well as on the Supervisory Board of Nabriva Therapeutics. From June 2006 until October 2007, Dr. Talbot served as Executive Vice President and Chief Medical Officer of Cerexa, Inc.. Dr. Talbot began his pharmaceutical career at Rhone-Poulenc Rorer, assuming positions of increasing responsibility as the company evolved into Aventis Pharmaceuticals. A Fellow of the Infectious Diseases Society of America and a member of the American Society for Microbiology, Dr. Talbot also has been elected a Fellow of the American College of Physicians. Dr. Talbot is a founding member of IDSA’s Antimicrobial Availability Task Force and has participated in recent joint meetings of IDSA and the FDA. Dr. Talbot previously was an Advisor to the Antimicrobial Susceptibility Testing Subcommittee of the Clinical and Laboratory Standards Institute (CLSI). Dr. Talbot has authored or co-authored over 80 original papers, plus numerous abstracts and several book chapters.